Study objective -The study aimed to determine whether asking women to undertake an additional scientific study would deter them from attending screening for breast cancer. 
In several European countries screening for breast cancer in women aged 50 years and over is routine. In The Netherlands two breast cancer screening projects have been operating since the mid 1970s.
I They both used mammography at regular intervals. A reduction in mortality from breast cancer as a result of screening was detected at the beginning of the 1980s in these and other projects.7 As a consequence screening for breast cancer became widespread in The Netherlands for women aged over 50. A high participation rate for screening is of the utmost importance if benefits are to be achieved in a population. 8 In general, older people tend to be more reluctant to participate than younger people, and participation rates may drop as screening becomes routine.9
To maintain as high a screening response rate as possible, women in The Netherlands are invited personally to attend for screening, and an appointment date is mentioned in the invitation letter. The location is planned to be within a distance of eight to 12 kilometres and the examination takes place in a special screening unit, preferably not attached to a hospital but rather to a local public community unit A feasibility study, the "prospect study," was carried out by the University of Utrecht. This study, which preceded EPIC, was associated with the breast cancer screening unit. Participation rates for screening were evaluated.
Peeters, Beckers, Hogervorst, Collette Methods Participation rates for breast cancer screening were evaluated in a randomised controlled study. A random sample of 3726 women was selected from the total female population of the city of Utrecht aged 50-70 years (n = 24 600).
They were randomly divided into two groupsr:
1863 women received their usual invitation for routine mammography (control group) and the remainder (prospect study group) were invited for the usual screening and for the additional procedures necessary for the EPIC study. For reasons of privacy the names and addresses of the women invited for the prospect study were not passed to the investigators. Women were informed about the prospect study by means of a letter from the management of the screening centre sent out two to three weeks before the usual invitation for screening. This letter explained why the management of the screening unit wanted to draw the woman's attention to the prospect study. A letter from the researchers and information about the prospect study were also included. If a woman wanted to participate in the prospect study, she had to return a reply coupon to the screening unit, and her name was then passed to the investigators of the prospect study. Women willing to participate were then sent two questionnaires and were asked to fill them out at home and to bring them back if they were coming for a screening examination. The questionnaires included questions on their usual diet and other lifestyle habits (for example, use of alcohol and drugs, smoking, reproductive history, physical activity, and medical history). After the mammogra- Of all women invited for the screening examination and the prospect study (n = 1863), 415 attended for breast cancer screening only, 569 women attended for a mammography and participated in the prospect study, and eight women attended the prospect study only. These eight women all mentioned that they had not attended for screening because they were already under the surveillance of a hospital doctor.
Discussion
As screening for breast cancer becomes widespread in western countries, regional units become suitable for prospective epidemiological studies. Attaching research to these units must not influence participation rates, however, since as high rates for screening as possible are necessary to reduce breast cancer mortality maximally in the screened population.
This study shows that inviting women for scientific research in addition to a screening examination did not deter them from attending screening. The participation rate for screening in the study group was 53%, equal to the rate in a comparable control group. There was, however, a difference in attendance in women aged over 69 years. This was almost half in the study group compared with the rate in the control group. Perhaps for older women additional investigations become too much a burden. In The Netherlands it was decided not to continue inviting women over age 69 years for regular breast cancer screening examinations.'2 In addition, for the EPIC study it was decided not to include women aged over 69 because of the prospective design of the study.
It is possible that the attendance rate will fall in this prospect study group if they are invited again for screening in two years' time (that is, 1994). Possible negative feelings because of their invitation or participation, or both, in the prospect study may then cause a decrease in the attendance rate for breast cancer screening. Although this is not expected, attendance rates for screening in these women will be examined again in the future.
In most countries privacy regulations make it impossible to transfer names and addresses to others. In this study, names were transferred only after permission of the women themselves. The attendance rate for screening in this random sample of Utrecht women was 53%. This is the attendance rate after a first call. All women who did not respond to their first invitation were invited again soon after and the attendance rate usually increased to approximately 60%. Attendance rates of women living in cities in The Netherlands tend to be somewhat lower than rates in women living in the country. Attendance rates for the total female population in Utrecht, after their first call for a screening examination, in the years 1989, 1990, and 1991 respectively were 53%, 54%, and 54%. The present sample seems to be a representative sample in terms of overall attendance rates.
By January 1993, all women who still had not attended for a screening examination after a reminder were invited again. The attendance rate for screening, including screening visits after a second call, was 61 % in both the prospect and control groups.
Some 58% of women (569 of 984) who came for a screening examination decided to participate in the additional prospect study. This study took one hour at home for filling out questionnaires and about half an hour extra at the screening centre. Also a blood sample was taken. This was known to the women before they made the decision to participate. Also it was strongly emphasised to these women that screening for breast cancer was in no way related to the prospect study, and that they were free to choose to participate in either one or both.
For the management of the prospect study, close cooperation with the screening unit was necessary. Only in this way was it possible to schedule prospect interviews jointly with screening examinations so that participating women only had to make one visit to the screening centre.
The participation rate in the prospect study was 31% (577 of 1863). This percentage is satisfactory, considering the age distribution of the invited population and the burden of the study (time consuming and taking blood samples). The rate will rise in the future for EPIC, since in The Netherlands women over age 69 years will not be invited. Also special press campaigns will possibly increase participation.
This study shows that inviting women for a prospective study additional to a screening examination does not deter them from attending screening, provided that proper invitation procedures are executed. 
